Whitehawk Therapeutics (WHWK) Cash from Investing Activities (2016 - 2026)

Whitehawk Therapeutics (WHWK) has reported Cash from Investing Activities for 11 consecutive years, with $19.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 83.18% year-over-year to $19.4 million; the TTM figure through Mar 2026 stood at -$84.2 million (down 164.68% YoY), while the FY2025 annual figure was $11.9 million, down 52.82% from the prior year.
• Cash from Investing Activities climbed to $19.4 million in Q1 2026 per WHWK's latest filing, from $16.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $115.5 million in Q1 2025 and bottomed at -$91.6 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged $402529.4 across 5 years, with a median of $5.1 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 183332.61% — and 2023, when it jumped 71095.65%.
• Whitehawk Therapeutics' Cash from Investing Activities stood at -$84.4 million in 2022, then soared by 104.32% to $3.6 million in 2023, then surged by 259.91% to $13.1 million in 2024, then grew by 28.27% to $16.8 million in 2025, then increased by 15.34% to $19.4 million in 2026.
• Business Quant data shows WHWK's Cash from Investing Activities at $19.4 million in Q1 2026, $16.8 million in Q4 2025, and -$91.6 million in Q3 2025.